Last edition
News about "Gazyvaro "
Roche's Gazyva Receives US FDA Priority Review for Membranous Nephropathy
The US Food and Drug Administration (FDA) has granted Priority Review to Roche's Gazyva for primary membranous nephropathy, supported by phase 3 MAJESTY trial results showing superior complete remission versus tacrolimus.
Gazyvaro | 17/07/2026 | By News Bureau
Roche's Gazyva/Gazyvaro Shows Positive Results for Systemic Lupus Erythematosus in Phase III trials
The ALLEGORY study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva/Gazyvaro versus standard therapy.
Gazyvaro | 05/11/2025 | By Dineshwori | 341
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy